One of the pa tients, who re ceived 11 doses, was an obese 80-kg boy aged 8 years. With dos age ti tra tion over a 2-day pe riod, an ap pro pri ate 7-mg dose IM was reached. He did ex hibit some ex trapy ra mi dal symp toms 2 hours af ter the first 7-mg dose and re sponded to 2 mg of oral benz tro pine.
One fe male pa tient ex hib ited a hy potensive epi sode 4.5 hours af ter a 1.9-mg dro peri dol dose, but 3 hours prior to droperi dol, she had also been given 2 mg of lo raze pam and 4 mg of ha loperi dol. Respi ra tory de pres sion was not seen in any pa tient. Drowsi ness (46 points), restless ness (14 points), and nerv ous ness (11 points) were the most com mon side ef fects re corded. All other side-effects scored < 5 points.
Our pre limi nary data show dro peri dol to be a safe and ef fec tive choice for acute agi ta tion in a small and het ero ge ne ous sam ple of chil dren and ado les cents. Further in ves ti ga tions, in clud ing ran domized con trolled tri als, are war ranted in this sub popu la tion. 
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Atypical Antipsychotics and Neuroleptic Malignant Syndrome
Dear Edi tor
I read with some in ter est the let ter, "Suspected Neu ro lep tic Cata to nia In duced by Clo zap ine," by Bi an cosino and others in the June is sue (1) . The authors report a case of clozapine-induced cata to nia as pos si bly the first case of typi cal cata tonic syn drome with out signs of neu ro lep tic ma lig nant syndrome (NMS), con comi tant to clo zap ine treat ment. The case pre sented with catatonic symp toms with lit tle ri gid ity and with out any auto nomic in sta bil ity. The authors pro pose that this case could be con sid ered as a mild form of Neu ro lep tic In duced Cata to nia (NIC) and warn of the risk of un der es ti mat ing the pro gres sion from NIC to NMS in such cases. Phillbrick and Rum mans (2) sug gest us ing the term "ma lig nant cata to nia" (not all cases are le thal) to de scribe cases charac ter ized by auto nomic in sta bil ity or hyper ther mia in con tra dis tinc tion to "sim ple," non ma lig nant cata to nia. Although there may be few sub tle dif ferences in pres en ta tion, NMS and le thal cata to nia ap pear to be part of a sin gle syn drome.
Sachdev and oth ers (3) con cluded that NMS does oc cur with clo zap ine, but may pres ent with fewer mo tor mani festa tions and milder cre atine ki nase (CK) ele va tions. In the case re ported by Bi ancosino and oth ers, cre atine phos phokinase was nor mal. Hasan and Buck ley (4) con curred that NMS may de velop with clo zap ine and risperi done, but sug gested that the oc cur rence of atypi cal forms of NMS with these drugs was un proven.
In view of re ports of NMS with clo zapine, risperi done, ol an zap ine, and quetiapine, Ca roff and oth ers (5) ex am ined some criti cal ques tions of sig nifi cance to prac tis ing cli ni cians. This in cludes the risk of clas sic NMS de vel op ing with atypi cal an tipsy chot ics. Do atypi cal antipsy chot ics re sult in atypi cal forms of NMS? Is the risk of NMS re duced with atypi cal drugs? Can the oc cur rence of NMS with atypi cal an tipsy chot ics pro vide us with fur ther in sights into the pa tho physi ol ogy of NMS?
Their re sults show that there are at least 30 cases of NMS as so ci ated with clo zapine in the lit era ture. Com pared with cases of NMS as so ci ated with other atypi cal and typi cal an tipsy chot ics, cases of NMS in duced by clo zap ine showed a simi lar course and dis tri bu tion of find ings, ex cept for a sig nifi cant decrease in the fre quency in which tremor was de scribed. Ab nor mali ties of CK were simi lar across all 4 treat ment groups. Col lec tively, atypi cal drugs were sig nifi cantly less likely than typical drugs to as so ci ate with tem pera tures ex ceed ing 38 C. Al though all cases as soci ated with atypi cal an tipsy chot ics met broad cri te ria for NMS, some pa tients pre sented with only par tial or in complete pic tures of NMS, lack ing ri gid ity or other fea tures. De spite these dif ferences, the ques tion as to whether atypical drugs are more likely to pro duce atypi cal forms of NMS re mains moot. Even with typi cal drugs, the pres en tation of NMS has of ten been vari able and het eroge nous, with some pa tients di agnosed with out ri gid ity, fe ver, or other fea tures. Like wise, milder, par tial, or atypi cal forms may be less spe cific for NMS, thus dif fi cult to dis tin guish from other more com mon and be nign side effects. This is par ticu larly true for clo zapine, which has been as so ci ated with be nign tem pera ture ele va tions with out ex tra py ra mi dal signs in 25% to 50% of pa tients and tachy car dia in 25% of patients (6) .
The case re ported by Bi an cosino and oth ers was suc cess fully man aged by stop ping the neu ro lep tic (clo zap ine) and treated with lo raze pam. In the ben zo diazepine treat ment of cata to nia, Bush and oth ers (7) spe cifi cally sug gested a trial of lo raze pam with res pi ra tory status moni tor ing. In a study of lo raze pam treat ment for NMS, ri gid ity and fe ver abated in 24 to 48 hours, wherein sec ondary fea tures of NMS were re lieved within 64 hours with out ad verse ef fects (8) . If lo raze pam is un suc cess ful, electro con vul sive ther apy should be con sidered as a de fini tive treat ment (9) .
That NMS oc curs at all with the atypi cal drugs sug gests that al though they re duce D 2 -r ece ptor po tency and other neu rotrans mit ter ef fects, this is not suf fi cient to pre vent all cases of NMS. This is most sur pris ing for clo zap ine, which shows D 2 -r ece ptor oc cu pancy that is sig nificantly lower than that of typi cal and other atypi cal an tipsy chot ics at therapeu ti cally ef fec tive dos ages (10) . The re chal lenged data also in di cates that NMS symp toms from both classes of drugs oc cur in the same pa tients, re flecting the same risks and un der ly ing pa thophysi ol ogy. De spite its weak D 2 -r ece ptor po tency, the oc cur rence of NMS with clo zap ine sug gests that NMS may oc cur in sus cep ti ble pa tients who have ge neti cally de ter mined, struc tural, or stress-related re duc tions in base line do pa mine ac tiv ity.
As atypi cal an tipsy chot ics are more widely used as first-line agents, more broad-based pro spec tive data on NMS with these drugs may be come avail able.
In the Ca roff re view of 44 pub lished cases that ful filled di ag nos tic cri te ria for NMS with atypi cal neu ro lep tics, it is clear that NMS can re sult from treat ment with atypi cal an tipsy chot ics and that it of ten pres ents with the clas sic fea tures and course of ill ness re ported pre vi ously in as so cia tion with typi cal an tipsy chotics. We must, how ever, also re mem ber as we switch pa tients from typi cal to atypi cal neu ro lep tics that the lin ger ing ef fect of re cent treat ment may be a fac tor in NMS de vel op ment with atypi cal drugs. It is un clear in Bi an cosino and oth ers' case re port if the clo zap ine treatment was pre ceded by any typi cal neu rolep tics. Sec ond, the pe riod af ter dis con tinua tion of an tipsy chot ics may rep re sent a pe riod of in sta bil ity in do pamin er gic sys tems.
I hope that this brief re view of the lit erature will add fur ther in ter est and perspec tive to the case re port pre sented by Bi an cosino and oth ers in the June journal.
Bruno Biancosino, MD Luigi Grassi, MD Ferrara, Italy
Treatment of Mixed Mania with Risperidone and Mood Stabilizers
Dear Edi tor:
Con ven tional treat ments for bi po lar disor der (an tipsy chot ics, an ti de pres sants, and mood sta bi liz ers), while be ing ef fica cious, lead to the oc cur rence of un desir able side ef fects, in clud ing ex tra py ra mi dal symp toms (EPS), tardive dyski ne sia (TD), an ti cho liner gic symp toms, and weight gain. The novel an tipsy chot ics, such as risperi done, may bene fit pa tients with bi po lar dis or der sub stan tially. Risperi done has proven to be ef fec tive in schizo phre nia (1) and also dem on strated ef fi cacy against the symp toms of anxi ety and de pres sion in these pa tients (2), while dis play ing a
